GOTHENBURG, Sweden, Sept. 3, 2024 /PRNewswire/ — SKF announces the appointment of Susanne Larsson as Senior Vice President and Chief Financial Officer of SKF Group. Susanne will join SKF, at the latest, in the beginning of March 2025. This follows the previous announcement that Niclas Rosenlew, the current CFO, will leave SKF in the beginning of 2025.

Susanne has experience from similar positions in global companies including the medical device company Mölnlycke Health Care and the security company Gunnebo. Previously, she has also held various senior positions within SKF.

"I’m happy to welcome Susanne back to SKF and look forward to working together. She will play a key role in our exciting journey forward," says Rickard Gustafson, President and CEO.

Susanne has led many financial and strategic change management initiatives and will provide valuable contribution to the ongoing transformation of SKF.

"I am excited to return to SKF and to contribute to the strategy execution, drive financial performance and further develop SKF’s decentralized organizational structure," says Susanne Larsson.

Aktiebolaget SKF (publ)

CONTACT:

For further information, please contact:PRESS: Carl Bjernstam, Head of Media Relationstel: 46 31-337 2517; mobile: 46 722-201 893; e-mail: carl.bjernstam@skf.com 

INVESTOR RELATIONS: Sophie Arnius, Head of Investor Relationstel: 46 31-337 8072; mobile: 46 705-908 072; sophie.arnius@skf.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skf/r/skf-announces-changes-to-group-management,c4032292

The following files are available for download:

https://mb.cision.com/Main/637/4032292/2977928.pdf

20240903 SKF announces changes to Group Management

https://news.cision.com/skf/i/susanne-larsson,c3329898

Susanne Larsson

https://news.cision.com/skf/i/skf-rickard-gustafson,c3329897

SKF Rickard Gustafson

 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session

SUZHOU, China, Oct. 18, 2025 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK)…

Bitget Turns Up the Heat on Earnings Season with Zero-Fee U.S. Stock Token Trading

VICTORIA, Seychelles, Nov. 3, 2025 /PRNewswire/ — Bitget, the world’s largest Universal…

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles…